1. Higginbotham EJ. Topical Carbonic anhydrase inhibitors. New ophthalmic drugs. Ophthalmol Clin North Am. 1989;2:113-130.

2. Maren TH. The rates of movement of Na+, Cl- and HCO3- from plasma to posterior chamber: effect of acetazolamide and relation to the treatment of glaucoma. Invest Ophthalmol. 1976;15:356-364.

3. Caprioli J. The ciliary epithelia and aqueous humor. In: Hart WM Jr, ed. Adler's Physiology of the Eye: Clinical Application. 9th ed. St Louis, MO: CV Mosby Co; 1992:234.

4. Friedman Z, Krupin T, Becker B. Ocular and systemic effects of acetazolamide in nephrectomized rabbits. Invest Ophthalmol Vis Sci. 1982;23:209-213.

5. Maren TH, Haywood JR, Chapman SK, Zimmerman TJ. The pharmacology of methazolamide in relation to the treatment of glaucoma. Invest Ophthalmol Vis Sci. 1977;16:730-742.

6. Stone RA, Zimmerman TJ, Shin DH, et al. Low-dose methazolamide and intraocular pressure. Am J Ophthalmol. 1977;83:674-679.

7. Dahlen K, Epstein DL, Grant WM, et al. A repeated dose-response study of methazolamide in glaucoma. Arch Ophthalmol. 1978;96:2214-2218.

8. Merkle W. Effect of methazolamide on the intraocular pressure of patients with open-angle glaucoma. Klin Monatsbl Augenheilkd. 1980;176:181-185.

9. Heller I, Halevy J, Cohen S, Theodor E. Significant metabolic acidosis induced by acetazolamide: not a rare complication. Arch Intern Med. 1985;145:1815-1817.

10. Margo CE. Acetazolamide and advanced liver disease. Am J Ophthalmol. 1986;101: 611-612.

11. Block ER, Rostand RA. Carbonic anhydrase inhibition in glaucoma: hazard or benefit for the chronic lunger? Surv Ophthalmol. 1978;23:169-172.

12. Lichter PR, Musch DC, Medzihradsky F, Standardi CL. Intraocular pressure effects of carbonic anhydrase inhibitors in primary open-angle glaucoma. Am J Ophthalmol. 1989;107:11-17.

13. Fraunfelder FT, Grove JA, eds. Drug-Induced Ocular Side Effects. Baltimore, MD: Williams & Wilkins; 1996:439-441.

14. Arrigg CA, Epstein DL, Giovanoni R, Grant WM. The influence of supplemental sodium acetate on carbonic anhydrase inhibitor-induced side effects. Arch Ophthalmol. 1981;99:1969-1972.

15. Maren TH, Ellison AC. The teratological effect of certain thiadiazoles related to acetazolamide, with a note on sulfanilamide and thiazide diuretics. Johns Hopkins Med J. 1972;130:95-104.

16. Kass MA, Kolker AE, Gordon M, et al. Acetazolamide and urolithiasis. Ophthalmology. 1981;88:261-265.

17. Shields MB, Simmons RJ. Urinary calculus during methazolamide therapy. Am J Ophthalmol. 1976;81:622-624.

18. Werblin TP, Pollack IP, Liss RA. Blood dyscrasias in patients using methazolamide (Neptazane) for glaucoma. Ophthalmology. 1980;87:350-354.

19. Wisch N, Fischbein FI, Siegel R, et al. Aplastic anemia resulting from the use of carbonic anhydrase inhibitors. Am J Ophthalmol. 1973;75:130-132.

20. Zimran A, Beutler E. Can the risk of acetazolamide-induced aplastic anemia be decreased by periodic monitoring of blood cell counts? Am J Ophthalmol. 1987;104: 654-658.

21. Fraunfelder FT, Meyer SM, Bagby CG Jr, Dreis MW. Hematologic reactions to carbonic anhydrase inhibitors. Am J Ophthalmol. 1985;100:79-81.

22. Foss RH. Local application of Diamox: an experimental study of its effect on the intraocular pressure. Am J Ophthalmol. 1955;39:336.

23. Ingram C, Brubaker RF. Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes. Am J Ophthalmol. 1999;128:292-296.

Friedman Z, Allen RC, Raph SM. Topical acetazolamide and methazolamide delivered by contact lenses. Arch Ophthalmol. 1985;103:963-966.

Lewis RA, Schoenwald RD, Eller MG, et al. Ethoxzolamide analogue gel: a topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1984;102:1821-1824. Stein A, Pinke R, Krupin T, et al. The effect of topically administered carbonic anhydrase inhibitors on aqueous humor dynamics in rabbits. Am J Ophthalmol. 1983;95: 222-228.

Kalina PH, Shetlar DJ, Lewis RA, et al. 6-Amino-2-benzothiazole-sulfonamide: the effect of a topical carbonic anhydrase inhibitor on aqueous humor formation in the normal human eye. Ophthalmology. 1988;95:772-777.

Hageman GS, Zhu XL, Waheed A, Sly WS. Localization of carbonic anhydrase IV in a specific capillary bed of the human eye. Proc Natl Acad Sci USA. 1991;88:2716-2720. Sugrue MF, Mallorga P, Schwam H, et al. A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals. Curr Eye Res. 1990;9:607-615.

Wang RF, Serle JB, Podos SM, Sugrue MF. The ocular hypotensive effect of the topical carbonic anhydrase inhibitor L-671,152 in glaucomatous monkeys. Arch Ophthalmol. 1990;108:511-513.

Wang RF, Serle JB, Podos SM, Sugrue MF. MK-507 (L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Arch Ophthalmol. 1991;109:1297-1299.

Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol. 1995;113:1009-1016.

Nardin G, Lewis R, Lippa EA, et al. Activity of the topical CAI MK-507 bid when added to timolol bid. Invest Ophthalmol Vis Sci. 1991;32(suppl):989. Strahlman EL, Tipping RW, Clineschmidt CM. A controlled clinical trial comparing dorzolamide (MK-507) and pilocarpine as adjunctive therapy to timolol. Ophthalmology. 1994;101(suppl):129.

Lippa EA, Schuman JS, Higginbotham EJ, et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Ophthalmology. 1992;110: 495-499.

Ott EZ, Mills MD, Arango S, et al. A randomized trial assessing dorzolamide in patients with glaucoma who are younger than 6 years. Arch Ophthalmol. 2005;123(9): 1177-1186.

Adamsons I, Clineschmidt C, Polis A, et al. The efficacy and safety of dorzolamide as adjunctive therapy to timolol maleate gellan solution in patients with elevated intraocular pressure. Additivity Study Group. J Glaucoma. 1998;7:253-260. Delaney YM, Salmon JF, Mossa F, et al. Periorbital dermatitis as a side effect of topical dorzolamide. Br J Ophthalmol. 2002;86(4):378-380.

Wilkerson M, Cyrlin M, Lippa EA, et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1993;111:1343-1350.

Kitazawa Y, Shimizu U, Ido T. MK-417 and MK-507, topical CAIs: the effect of lowering intraocular pressure and the pharmacokinetics in normal volunteers. Presented at: International Glaucoma Symposium; August 20, 1991; Jerusalem, Israel. Lass JH, Khosrof SA, Laurence JT, et al. A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group. Arch Ophthalmol. 1998;116:1003-1010.

42. Konowal A, Morrison JC, Brown SVL, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol. 1999;127:403-406.

43. Maus TL, Larsson LI, McLaren JW, Brubaker RF. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol. 1997;115:45-49.

44. Kitazawa Y, Azuma I, Araie M, et al. Topical dorzolamide hydrochloride can be a substitute for oral CAIs [abstract]. Invest Ophthalmol Vis Sci. 1994;35(suppl):2177.

45. Hutzelmann JE, Polis AB, Michael AJ, Adamsons IA. A comparison of the efficacy and tolerability of dorzolamide and acetazolamide as adjunctive therapy to timolol. Acta Ophthalmol Scand. 1998;76:717-722.

46. Rosenberg LF, Krupin T, Tang LQ, et al. Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation. Ophthalmology. 1998;105:88-93.

47. Harris A, Arend O, Arend S, Martin B. Effect of topical dorzolamide on retinal and retrobulbar hemodynamics. Acta Ophthalmol Scand. 1996;74:569-574.

48. Nagel E, Vilser W, Lanzl I. Dorzolamide influences the autoregulation of major retinal vessels caused by artificial intraocular pressure elevation in patients with POAG: a clinical study. Curr Eye Res. 2005;30(2):129-137.

49. The European Glaucoma Prevention Study Group. Results of the European Glaucoma Prevention Study. Ophthalmology. 2005;112:366-375.

50. Kass MA, Heuer DK, Higginbotham EJ, et al. Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study. A randomized trial determines that topical hypotensive medication delays or prevents the onset of primary open angle glaucoma. Arch Ophthalmol. 2002;120:701-713.

51. Tsukamot H, Noma H, Mukai S, et al. The efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in combination therapy with latanoprost, timolol, and dorzolamide. J Ocul Pharmacol Ther. 2005;21(5):395-399.

52. Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol. 1998;126:400-408.

53. van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs. a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112(7):1177-1185.

54. McCarty GR, Dahlin D, Curtis M, et al. A double-masked, parallel group, placebo-controlled, multiple-dose pharmacokinetic study of brinzolamide following oral administration in normal volunteers [abstract 3246]. Invest Ophthalmol Vis Sci. 1998; 39:707.

55. Stewart R; Brinzolamide Comfort Study Group. The ocular comfort of TID-dosed brinzolamide 1.0% compared to tid-dosed dorzolamide 2.0% in patients with primary open-angle glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 1997;38: 559.

Blood Pressure Health

Blood Pressure Health

Your heart pumps blood throughout your body using a network of tubing called arteries and capillaries which return the blood back to your heart via your veins. Blood pressure is the force of the blood pushing against the walls of your arteries as your heart beats.Learn more...

Get My Free Ebook

Post a comment